Acute Myeloid Leukemia: Symptoms, Causes and Care

<a href="https://acibademhealthpoint.com/diseases/acute-myeloid-leukemia/”>Acute myeloid leukemia (AML) is a cancer of the blood-forming cells in bone marrow that can develop quickly and requires prompt specialist assessment. Treatment is individualized and may include chemotherapy, targeted medicines, stem cell transplantation and supportive care.

Can you provide an overview of acute myeloid leukemia?

Acute myeloid leukemia, often called AML, is a cancer that starts in the bone marrow, the soft tissue inside bones where blood cells are made. In AML, immature myeloid cells develop abnormal genetic changes and multiply too quickly. These leukemia cells can build up in the marrow and blood, leaving less room for healthy red blood cells, white blood cells and platelets.

The word acute means AML can progress over weeks or months rather than slowly over years. It is therefore important to investigate concerning symptoms promptly. AML occurs most often in older adults, but it can develop at any age, including in children and younger adults.

There are several AML subtypes. Doctors classify AML using the appearance of the cells, chromosome changes and gene mutations within leukemia cells. This detailed testing is important because it helps estimate risk and guide an individual treatment plan. AML differs from other blood cancers, including chronic myeloid leukemia, which generally has a different pattern of development and treatment approach.

Is AML a serious cancer?

AML is a serious cancer because it may develop rapidly and can affect the body’s ability to make normal blood cells. Low red blood cell levels can cause anemia and fatigue, low white blood cell levels can increase infection risk, and low platelets can lead to bruising or bleeding. However, seriousness does not mean that treatment is ineffective or that outcomes are the same for every person.

Many factors influence outlook, including a person’s age and general health, whether AML developed after another bone marrow condition or previous cancer treatment, and the genetic characteristics of the leukemia cells. Modern care uses detailed molecular testing to identify treatments that may be more suitable for particular AML subtypes.

AML treatment is usually coordinated by hematologists and oncology specialists with experience in blood cancers. It can involve intensive treatment in hospital, lower-intensity approaches for selected people, or medicines designed to target specific changes in leukemia cells. Supportive care, including transfusions and infection prevention, is an essential part of treatment.

What are the first signs of AML?

The first signs of AML are often nonspecific, meaning they may also occur with common illnesses. Symptoms result mainly from reduced production of normal blood cells. Persistent tiredness, weakness, pale skin, dizziness and becoming short of breath with everyday activity can be signs of anemia.

Frequent infections, fevers, chills or infections that are unusually difficult to recover from may occur when healthy infection-fighting white blood cells are low or not functioning normally. Easy bruising, pinpoint red or purple spots on the skin, nosebleeds, bleeding gums or heavier-than-usual menstrual bleeding can happen when platelet counts fall.

Some people also have reduced appetite, unintentional weight loss, night sweats, bone or joint discomfort, or a feeling of fullness in the abdomen. These symptoms do not confirm AML, and many have other causes. Still, a clinician should assess symptoms that persist, worsen or occur together, particularly unexplained bruising, bleeding, fever or marked fatigue.

• Ongoing fatigue, weakness or breathlessness
• Repeated infections, fever or chills
• Unexplained bruising, bleeding or tiny red skin spots
• Pale skin, dizziness or a racing heartbeat
• Unintended weight loss, night sweats or bone discomfort

What is the main cause of AML leukemia?

There is no single main cause of AML leukemia for most individuals. AML develops when blood-forming cells acquire genetic changes that affect how they grow, mature and survive. These changes are usually acquired during life rather than inherited directly from a parent, and people should not assume that anything they did caused the condition.

In many cases, doctors cannot identify why a particular person developed AML. Known factors associated with a higher risk include increasing age, some previous blood or bone marrow disorders, and prior treatment with certain chemotherapy medicines or radiation therapy. Exposure to high levels of benzene, a chemical used in some industrial settings, is also a recognized risk factor.

Smoking may increase AML risk, and some rare inherited conditions can raise the likelihood of leukemia. Having a risk factor does not mean a person will develop AML, while many people diagnosed with AML have no clear risk factors. Genetic tests performed after diagnosis examine the leukemia itself and are different from testing family members for inherited conditions.

How AML is diagnosed and classified

Assessment commonly starts with a medical history, physical examination and complete blood count. A blood test may show abnormal numbers of red cells, white cells or platelets, and sometimes immature cells called blasts are visible in the bloodstream. Blood test results alone cannot always establish the exact diagnosis.

A bone marrow aspiration and biopsy are usually needed to confirm AML. During this procedure, a clinician takes samples of liquid marrow and a small core of marrow, often from the back of the hip bone. The samples are studied using microscopy, flow cytometry, chromosome testing and molecular genetic tests.

These tests identify the AML subtype and mutations that may affect treatment choices. Doctors also evaluate heart, kidney and liver function, screen for infection when appropriate, and discuss fertility preservation before treatment if relevant. A careful diagnostic process helps the care team balance effectiveness, safety and a person’s individual priorities.

Treatment options and supportive care for AML

AML treatment is tailored to the subtype of leukemia and to the person receiving care. For people who are fit enough, initial intensive chemotherapy may be used to achieve remission, meaning leukemia cells are no longer detectable by standard tests and normal blood production can recover. Further treatment is commonly needed afterward to lower the chance of relapse.

Some AML types may be treated with targeted medicines that act on particular gene changes, and selected patients may receive lower-intensity drug combinations when intensive chemotherapy is not suitable. Acute promyelocytic leukemia, a specific AML subtype, has a distinct treatment approach and requires urgent specialist management because of its bleeding risks.

A bone marrow transplant—also called a stem cell transplant—may be considered for some people, especially when relapse risk is higher or AML returns after initial treatment. The potential benefits and risks depend on many factors, including the availability of a compatible donor, overall health and disease features.

Supportive care may include red blood cell or platelet transfusions, antibiotics or antiviral medicines when needed, management of nausea and nutrition, and monitoring for treatment side effects. Clinical trials may also be an option for eligible patients. Decisions should be made with a specialist team that can explain the expected goals, benefits and possible complications of each approach.

Living with AML and reducing preventable risks

There is no proven way to prevent most cases of AML because its underlying genetic changes often arise without a known cause. Avoiding tobacco, following workplace safety measures around chemicals such as benzene, and attending follow-up appointments after previous cancer treatment are sensible general steps that may reduce certain avoidable risks.

During AML treatment, the care team may advise practical measures to lower infection risk, especially when white blood cell counts are low. These can include careful hand hygiene, avoiding close contact with people who are unwell, following food-safety advice and reporting fever promptly. Patients should ask their clinical team before taking supplements, herbal products or over-the-counter medicines, as some may affect treatment or bleeding risk.

Emotional and practical support matters as well. Family, friends, oncology nurses, social workers, nutrition professionals and counseling services can help people manage appointments, symptoms, work or family responsibilities. Keeping a written list of symptoms and questions can make consultations easier and support shared treatment decisions.

When to seek medical care

Anyone with persistent unexplained fatigue, repeated infections, fever, easy bruising or unusual bleeding should arrange a medical assessment. These symptoms are common and are often caused by conditions other than AML, but a simple blood test can help identify whether further investigation is needed.

Urgent medical care is appropriate for heavy or uncontrolled bleeding, a fever in someone receiving chemotherapy, severe shortness of breath, chest pain, fainting, confusion or signs of a serious infection. People already diagnosed with AML should follow the emergency contact instructions given by their hematology team.

Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals provide diagnostic assessment and treatment for international patients with blood cancers, including AML. A hematology consultation can help clarify test results, explain treatment pathways and identify appropriate next steps.

Frequently asked questions